Immunotherapy (Pembrolizumab, Nivolumab)

Type: drug

Status: FDA Approved

Developer: Merck (Pembrolizumab), Bristol-Myers Squibb (Nivolumab)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026